Cytokinetics (CYTK) Cash & Current Investments (2016 - 2025)
Historic Cash & Current Investments for Cytokinetics (CYTK) over the last 16 years, with Q3 2024 value amounting to $1.0 billion.
- Cytokinetics' Cash & Current Investments rose 8755.39% to $1.0 billion in Q3 2024 from the same period last year, while for Sep 2024 it was $1.0 billion, marking a year-over-year increase of 8755.39%. This contributed to the annual value of $615.2 million for FY2023, which is 2154.85% down from last year.
- Cytokinetics' Cash & Current Investments amounted to $1.0 billion in Q3 2024, which was up 8755.39% from $1.1 billion recorded in Q2 2024.
- Cytokinetics' Cash & Current Investments' 5-year high stood at $1.1 billion during Q2 2024, with a 5-year trough of $213.1 million in Q2 2020.
- Moreover, its 5-year median value for Cash & Current Investments was $566.1 million (2023), whereas its average is $576.6 million.
- Its Cash & Current Investments has fluctuated over the past 5 years, first soared by 14708.89% in 2020, then plummeted by 3780.84% in 2023.
- Quarter analysis of 5 years shows Cytokinetics' Cash & Current Investments stood at $464.1 million in 2020, then grew by 1.63% to $471.6 million in 2021, then surged by 66.27% to $784.2 million in 2022, then fell by 21.55% to $615.2 million in 2023, then soared by 64.51% to $1.0 billion in 2024.
- Its Cash & Current Investments stands at $1.0 billion for Q3 2024, versus $1.1 billion for Q2 2024 and $619.3 million for Q1 2024.